Background: Clozapine remains the only evidence-based treatment for treatment-resistant schizophrenia, and prediction of clozapine response is important in developing stratified treatment. We studied potential predictors of clozapine response, applying functional assessments as well as service use.
pproximately one third of patients with schizophrenia will not respond to nonclozapine antipsychotic treatment, thus meeting criteria for treatment-resistant schizophrenia (TRS). 1 The criteria for TRS in most guidelines, for example, the UK National Institute for health and Care Excellence (NICE 2014, https:// www.nice.org.uk/guidance/cg178), are failure to respond to 2 different antipsychotics at therapeutic dosages for a sufficient duration. 1, 2 In the case of TRS, guidelines recommend treatment with clozapine, the antipsychotic with proven superior effectiveness in this patient group. 3 Nevertheless, adherence to these guidelines is poor and varies geographically. 4, 5 Furthermore, recent studies have identified the problems of delays in clozapine initiation and underuse of clozapine in TRS, and there is a concern that delayed use may have a negative impact on longterm outcome. 1, 6 The identification of clinical variables predicting clozapine response has the potential to encourage timely treatment with clozapine, particularly in patients who are most likely to benefit. However, to date, the evidence regarding prediction of clozapine response is very limited. Early clozapine treatment initiation after fulfillment of TRS criteria, 7 a lower number of psychiatric hospitalizations and antipsychotic trials before clozapine treatment, 8 and an increase in triglyceride levels 9 have all been associated with clozapine response. The results on sex 10, 11 and age 12, 13 are conflicting. Furthermore, most studies to date have been underpowered. 7, 9 Finally, recent reviews have emphasized the importance of including functional outcomes 2, 14, 15 and quality of life assessments 16 in the evaluation of the clinical course of treatment.
We aim to identify potential predictors of clozapine response on the basis of both a service measure (no hospitalizations) and a functional measure (increments in the Global Assessment of Functioning [GAF-F] score). To our knowledge, this is the first study implementing these 2 clinically important dimensions in the prediction of the clinical course of clozapine treatment within a large nationwide setting.
MATERIALS AND METHODS

The Registers
The present population-based cohort study was performed by merging several Danish nationwide registers via the unique personal identification number assigned to all people living in Denmark permanently. 17 The registers represent well-validated resources for research. [17] [18] [19] [20] [21] Danish Psychiatric Central Research Register hospitals since 1995. The information includes dates of contacts and diagnoses, which are coded according to the International Classification of Diseases, Eight Edition, (ICD-8) up to 1994 and according to ICD-10 since then. 19 
Danish Schizophrenia Registry and the GAF
The Danish Schizophrenia Registry (DSR) 22, 23 was established in the Danish Healthcare System in 2003 and constitutes a registry on selected measures of quality of care in relation to people diagnosed with schizophrenia (ICD-10: F20.0-F20.9). All patients diagnosed with schizophrenia in Denmark since 2004, both inpatients and outpatients, are registered, except those treated in forensic mental health services. Since January 1, 2004, data on approximately 11,000 patients were recorded each year. A recent study documented high internal validity of the variables registered in the DSR when compared with information from medical records. 23 The GAF scale evaluates both symptom severity (GAF-S) and functioning (GAF-F), 24 ranking a patient from 1 (lowest score) to 100 on both scales. Within the DSR, GAF-F is used and is supposed to be registered at various times. Between January 1, 2004, and December 31, 2011, among patients admitted to a hospital, patients were GAF-F scored at discharge or after 1 year if the hospitalization lasted longer than 1 year. Among outpatient contacts, patients were GAF-F scored once yearly and/or at completion of the outpatient contact. The availability of registration of GAF-F scoring may therefore vary at defined dates for epidemiological studies during follow-up. The internal and external validity of the GAF-F score against measures of severity is good. 25 
Danish National Prescription Registry
The Danish National Prescription Registry (DNPR) registers all prescriptions issued at Danish community pharmacies since 1995 and records information, among others, on date of redemption, the anatomical therapeutic chemical code, amount, and drug name. 20 
Registers Used for Identification of Covariates
The Danish Civil Registration System provides information on date of birth, sex, and parents for each resident in Denmark since 1968. 17 Levels of educational achievements and occupational status are registered in the Danish Education Registers 18 and the Danish registers on personal labor market affiliation, 26 respectively.
Study Population
Using the Danish Psychiatric Central Research Register, 19 we identified all adult patients (≥18 years) born after January 1, 1955, and with a diagnosis of schizophrenia (ICD-10: F20.0-F20.9) in an inpatient or outpatient setting between January 1, 1995, and December 31, 2011.
We then used the DNPR 20 to identify those patients with schizophrenia who redeemed their first prescription of clozapine (Anatomical Therapeutic Chemical code: N05AH02), that is, who picked up their clozapine prescription at a Danish pharmacy, between January 1, 2004, and December 31, 2011. Clozapine initiation was defined as the date of redemption of the first clozapine prescription. We used the DSR 22 to identify those patients who had a registered GAF-F score within the 30 days before clozapine initiation. This score represented the GAF-F at baseline, that is, at clozapine treatment initiation.
Treatment Duration
Because prescribed dosage information was not available, the duration of clozapine treatment after each redemption of a clozapine prescription was estimated on the basis of the prescribed number and dose of pills and the defined daily dose or DDD. 27 We calculated the estimated treatment duration for each prescription as follows: treatment duration (days) = ([number of packages Â number of pills per package Â dose of pills]/DDD) Â 1.15 + 90. The multiplication factor of 1.15 and the addition of 90 days were included because these extensions of the treatment period are in closer agreement with actual drug consumption in clinical practice due to poor adherence. 28 Hence, if an individual did not redeem a new prescription for clozapine within the calculated time window (including the 90-day grace period, that is, the extra period to allow for low compliance or delayed redemption of the next clozapine prescription), clozapine treatment was considered discontinued. We followed all individuals for the first 2 years of clozapine treatment or until discontinuation.
Clinical Response Outcome
We assessed the clinical response to clozapine treatment by applying both a service use and a functional outcome measure. The service use outcome measure was defined as nonhospitalization with schizophrenia (ICD-10: F20.0-F20.9), that is, staying out of hospital during clozapine treatment. 19 The functional outcome measure was based on a recent study, which defined response to clozapine treatment via increments in the level of psychosocial functioning. 2 Using the DSR, 22, 23 we identified the highest GAF-F score achieved during clozapine treatment. The definition of functional response was the following 2 :
• Moderate improvement: GAF-F increase ≥10
• Substantial improvement: GAF-F increase ≥20 and total GAF-F ≥50.
Assessment of Predictors
We identified information on the following covariates at the time of the first clozapine prescription (baseline): sex and age, 17 education (primary school or higher education), 18 employment status (work force or early retirement pension), 26 marital status (single or married/cohabiting), and time since first schizophrenia diagnosis. 19 In addition, we assessed inpatient or outpatient contacts to psychiatric hospitals within 30 days of the first clozapine prescription and among inpatients the length of hospitalization in number of days. Furthermore, we identified whether the hospital contact happened during detainment, that is, whether any coercive measures were applied during the hospitalization.
Statistical Analyses
Concerning differences between individuals who were GAF-F scored and individuals without a registered GAF-F score, we performed logistic regression analyses on potential baseline differences at the time of the first clozapine prescription.
We followed all individuals from the day of the first clozapine prescription redeemed at a community pharmacy until the occurrence of an outcome (until December 31, 2011, for GAF-F scores and until June 30, 2013, for hospitalizations), death, emigration, discontinuation of clozapine treatment, or end of follow-up after 2 years. We performed Cox regression analyses to evaluate the relationship between the different variables at clozapine treatment initiation and clinical response. We report hazard rate ratios (HRRs) and 95% confidence intervals (95% CIs). The basic analytical model included age and sex. The full model included sex, age, marital status, education, work status, calendar year, time since first schizophrenia diagnosis until first clozapine prescription, inpatient or outpatient status including length of hospitalization and detainment.
Subanalyses and Sensitivity Analyses
Because previous studies have shown conflicting results on sex, 10, 11 we performed additional analyses stratified by sex.
In sensitivity analyses, we tested the robustness of our findings. First, we investigated whether the results changed when we only included GAF-F scores within the first 14 or 7 days before the first redeemed clozapine prescription or when we restricted to individuals with a GAF-F score registered on the day of the clozapine prescription redemption. Second, we investigated whether the results changed when we calculated the clozapine treatment duration applying a grace period of 30 days or when we added no grace period (instead of the 90-day grace period used for the primary analyses). Third, we only used the criterion of GAF-F improvement of 20 or greater as the definition of substantial improvement.
RESULTS
We identified 502 individuals with a diagnosis of schizophrenia between 1995 and 2011, who initiated clozapine treatment during 2004-2001 and who had a GAF-F score within 30 days before the first clozapine prescription (Fig. 1, flow chart) . The baseline characteristics of the sample are shown in Table 1 . A total of 378 individuals (75.5%) continued clozapine treatment throughout the 2-year follow-up period. Patients with a GAF-F score differed from those without as they were less often males (P = 0.09) and more often hospitalized (P = 0.06, Table 1 ).
Predictors of Nonhospitalization
Among the 502 patients who initiated clozapine treatment, 232 (46.2%) were not hospitalized because of schizophrenia during the follow-up period (Table 2 ). In the fully adjusted model, voluntary status (ie, no act of detainment) at clozapine initiation showed a tendency toward nonhospitalization (HRR, 1.61; 95% CI, 0.97-2.67). A hospitalization of more than 90 days before the first clozapine prescription, compared with clozapine initiation during an outpatient contact, indicated a lower risk for nonhospitalization (HRR, 0.70; 95% CI, 0.49-1.01). We found no associations for the other variables and in sex-specific analyses.
Predictors of Good Functional Improvement
A total of 96 individuals (19.1%) achieved a moderate functional improvement, and 29 individuals (5.8%) achieved substantial improvement during the study period ( 
Subanalyses and Sensitivity Analyses
Sex-specific subanalyses indicated that a shorter time from schizophrenia diagnosis to clozapine initiation was associated with substantial functional improvement among women. A total of 13 women achieved substantial improvement, and the chance of substantial improvement decreased by 15% (HRR, 0.85; 95% CI, 0.72-1.00) for each year delay in clozapine initiation after first schizophrenia diagnosis.
All sensitivity analyses for different time windows for identification of the GAF-F scores and different grace periods for calculation of clozapine treatment length supported our primary results. Finally, when using GAF-F improvement of 20 or greater as the sole criterion for substantial improvement, 35 individuals (7.0%) were classified with substantial improvement, and the results supported our primary findings.
DISCUSSION
The present study investigated a broad range of potential predictors for clozapine response among 502 patients with schizophrenia by evaluating service-based (no hospitalization with schizophrenia) and functional measures (increase in GAF-F). A total of 75% remained on clozapine treatment during the 2-year follow-up period. Of the patient and disease-related factors (ie, sex, age at first clozapine prescription, time from schizophrenia diagnosis to first clozapine prescription, inpatient or outpatient status at the hospitalization at clozapine initiation including length of hospitalization, detainment, marital status, education, work status, and calendar year), living with a partner was the strongest factor associated with better response to clozapine treatment. In addition, among women, a shorter time from schizophrenia diagnosis to clozapine initiation was associated with better functional improvement.
Predictors for Clozapine Response
A range of potential predictors for clozapine response have been identified to date, yielding conflicting results. 29 Living with a partner, indicating better premorbid functioning, predicted functional improvement in our study, which is in accordance with other studies associating better premorbid functioning with improved response to clozapine. 13 Furthermore, living with a partner may have resulted in a better adherence and thus better improvement. However, a recent review discussed that the level of premorbid functioning may not be particularly useful in clozapine response prediction. 29 The importance of the differentiation of premorbid functioning during different periods of life, that is, childhood or adolescence, was suggested to be more important. 13, 29 Regarding sex, several studies have associated women with better response to clozapine, 30 whereas others have reported either worse response compared with men 31 or no sex differences. 32 Our findings suggest that women may have a better functional improvement during clozapine treatment compared with men, although the results did not reach statistical significance. In addition, among women, we associated a shorter time from schizophrenia diagnosis to clozapine treatment initiation with a trend toward better functional improvement. This association was not present among men. The chance of reaching substantial improvement was deceased by 15% for each year delay in clozapine treatment initiation from first schizophrenia diagnosis. This result is in line with previous findings reporting better response among individuals who initiated clozapine treatment early after fulfillment of TRS criteria. 7 However, these authors did not find sex differences, 7 possibly because of low power (n = 162). Indeed, it has been documented that clozapine treatment often is delayed for several years among patients with TRS. 6 In addition, an underuse of clozapine has been emphasized among patients fulfilling TRS criteria including reluctance to initiate treatment with clozapine, potentially leading to delayed treatment. 1 Thus, future studies should investigate the importance of timing of clozapine treatment, that is, whether early clozapine treatment initiation, for example, after fulfillment of TRS criteria, is associated with improved response. Furthermore, it seems important to investigate the presence of possible sex differences concerning timing and treatment response patterns.
The absence of detainment was non-significantly associated with better rates of nonhospitalization and functional improvement in the current study. However, we had only information whether the hospital contact happened during detainment, not concerning the actual clozapine treatment initiation. Nevertheless, because clozapine treatment requires good compliance and acceptability due to frequent blood test monitoring, initiation of clozapine treatment during an act of detainment may be less likely to result in a good response pattern.
We found no effects of age at clozapine initiation on clozapine response. Finally, future studies need to investigate whether other important factors are associated with clozapine response, such as psychiatric and/or physical comorbidity and substance use.
Strengths and Limitations
The strengths are the population-based design and the wellvalidated Danish registers. 17, 19, 21 The DSR has an overall high validity, 33 including good internal validity for GAF-F. 25 Furthermore, we included both service-based and psychosocial measures of functioning in response evaluation, thereby trying to meet the high heterogeneity among patients with schizophrenia.
Concerning limitations, other measures of psychosocial functioning than the GAF-F, such as Global Impression Scale and the Positive and Negative Symptom Scale, are used in different clinical psychiatric settings. However, recent studies have found that The adjusted HRR was adjusted for the following: age at clozapine initiation, sex, time since schizophrenia diagnosis, calendar year of clozapine initiation, education, work status, inpatient or outpatient status at hospitalization within 30 days before clozapine initiation, length of the hospitalization before first clozapine prescription if clozapine treatment was initiated after an inpatient hospitalization, detainment at the hospitalization within 30 days before clozapine initiation, and marital status.
CLZ indicates clozapine; ref, reference.
the GAF-F has a high validity and correlates well with the Global Impression Scale and the Positive and Negative Symptom Scale. 15, 34, 35 Nevertheless, the GAF-F cannot be directly translated to the other scores, and future studies need to investigate other scores of functioning, psychopathology, 36, 37 and quality of life. 16 Secondly, within the Danish Schizophrenia Register, the GAF-F is only registered at specific times. During our study period, among hospitalized patients, every patient was supposed to have a GAF-F score registered at discharge or after 1 year if the hospitalization lasted longer than 1 year. Among outpatient contacts, a GAF-F score was supposed to be performed once yearly and at completion of the outpatient contact. Therefore, the present study included more patients (70%) who had been inpatients within the 30 days before filling their first prescription for clozapine (P = 0.06 compared with individuals without a GAF-F score) and thus, potentially, a cohort of more severely ill patients. Furthermore, these predefined assessment times may have prevented patients to be GAF-F scored during periods of improvement, potentially resulting in an underreporting of cases with functional improvement. However, our results were robust in sensitivity analyses with different assessments of the baseline GAF-F score. In addition, we found no important baseline differences between individuals with a GAF-F score and individuals without a registered GAF-F score (Table 1) .
Third, the DNPR 20 holds only information on the redemption of prescriptions, not the actual consumption or specific dosage regimen. However, the methods used in the present study regarding calculation of treatment length have been evaluated as clinically relevant. 28 Furthermore, we applied different time windows for calculation of clozapine treatment duration, which did not change the results.
Fourth, because of lack of information on hospital treatment, we do not know whether clozapine treatment was initiated during an inpatient stay so that the assessed GAF-F score within 30 days before the first clozapine outpatient prescription may not actually represent precise preclozapine functioning.
Fifth, response to clozapine is at least partly mediated through blood clozapine concentrations, 29 but we had no information on clozapine blood levels. Sixth, we did not include information on other psychotropic medications, which may have biased our findings; however, the evidence concerning the efficacy of clozapine augmentation strategies is limited. 38 Finally, although applying large databases, we had low power for several of the investigated predictors because of few events.
Conclusion and Perspectives
Living with a partner was the strongest predictor of improved functioning after clozapine initiation in this study. Although potentially indicating better premorbid functioning in general, this finding stresses the need and importance of social support during the course of the treatment independent of clinical factors. Furthermore, among women, each year delay in clozapine treatment initiation after first schizophrenia diagnosis resulted in a 15% lower chance of reaching substantial functional improvement. Hence, it is important to investigate whether some patients may benefit from an earlier initiation with clozapine treatment and whether this differs among men and women. Functional outcomes were assessed as moderate improvement (increase in GAF-F ≥10) and substantial improvement (increase in GAF-F ≥20 and a GAF-F ≥50).
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